Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer
Clin. transl. oncol. (Print)
; 10(9): 583-586, sept. 2008.
Article
em En
| IBECS
| ID: ibc-123522
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
INTRODUCTION:
Metronomic chemotherapy combined with bevacizumab has proved to be effective in various tumour types. The aim of this study is to review our experience in recurrent ovarian carcinomas treated with low-dose cyclophosphamide and bevacizumab. MATERIALS ANDMETHODS:
Retrospective analysis of pre-treated ovarian cancer patients, i.e., > or =2 previous chemotherapy regimens who received treatment with oral cyclophosphamide 50 mg/day and bevacizumab 10 mg/kg IV every two weeks. Patients with a performance status 0-2 were included. The endpoints were response rates, progressionfree disease and safety profile.RESULTS:
Nine patients with advanced, measurable ovarian cancer were included. Of these, 8 were platinum-resistant and had received prior regimens with gemcitabine (88%), topotecan (77%) and liposomal doxorubicin (66%). There was a mean of 5 previous lines of chRESUMEN
No disponible
Buscar no Google
Coleções:
06-national
/
ES
Base de dados:
IBECS
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article